For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 16,744 | |||
| General and administrative | 13,660 | |||
| Total operating loss | 30,404 | |||
| Interest income | 3,920 | |||
| Realized gain on sale of marketable securities, net | 119 | |||
| Gain (loss) on change in fair value of derivative instruments | 1,161 | |||
| Total non-operating income | 5,200 | |||
| Loss before income tax | -25,204 | |||
| Income tax provision | 1 | |||
| Net loss | -25,205 | |||
| Basic EPS | -3.13 | |||
| Diluted EPS | -3.13 | |||
| Basic Average Shares | 8,045,145 | |||
| Diluted Average Shares | 8,045,145 | |||
LB PHARMACEUTICALS INC (LBRX)
LB PHARMACEUTICALS INC (LBRX)